Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF

General Info

Geography

United States of America (USA)

Time period covered

January, 2003 - December, 2012

Data type

Scientific literature

Keywords

Chemotherapy, Health care costs, Multiple myeloma

Citation

Authors

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M

Journal

J Clin Apher

Pages

359-67

Publication year

2013

Suggested citation

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013; 28(5): 359-67.